Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Cancers|October 29, 2025
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2- Metastatic Breast Cancer: A Real-World Multicenter StudyPalma Fedele, Matteo Landriscina, Lucia Moraca, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 24, 2019
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancerGuido Giordano, Pietro Parcesepe, Mario Rosario D'Andrea, et al.
Genes|May 27, 2023
Loss of Primary Cilia Potentiates <i>BRAF/MAPK</i> Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (<i>CROCC</i>) AlterationsAndrea Remo, Federica Grillo, Luca Mastracci, et al.
Cancers|October 26, 2024
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter StudyPalma Fedele, Matteo Landriscina, Lucia Moraca, et al.
Frontiers in Oncology|May 21, 2025
Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitorsMarianna Caterino, Giorgio Lo Giudice, Vincenzo Damiano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 13, 2024
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real lifeMichele Reni, Guido Giordano, Marco Audisio, et al.
The Oncologist|October 16, 2016
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical OutcomesFrancesco Giotta, Luigi Acito, Giampiero Candeloro, et al.
Tumori|December 19, 2019
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceEufemia S Lutrino, Laura Orlando, Antonio Febbraro, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genesAnna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
Journal of Hepatology|July 5, 2026
Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE studyDo-Youn Oh, Masafumi Ikeda, Teresa Macarulla, et al.
Pageof 11